Osmessn.com

In a video interview with Pharma Commerce, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, addresses the potential impacts of a federal cap on Medicaid provider taxes and how such a policy could affect hospital systems. particularly in states like Michigan that have uniquely […]

In this Pharmaceutical Commerce roundtable discussion, Nicholas Saraceno, editor of Pharmaceutical Commerce and the peer exchange’s moderator, introduced a discussion on the pharmaceutical supply chain, highlighting its complexity and importance in delivering medications safely and efficiently from manufacturers to patients. The conversation explored the roles of various stakeholders, the need for supply chain resilience and quality control, […]

PC: In the absence of public participation at the federal level, how can industry leaders collaborate with advocacy groups to sustain meaningful engagement with regulators? Leuchter: Experienced regulators are very attuned to how patients and caregivers live day to day with a given disease. That understanding is a key part of how they evaluate opportunities […]

In a video interview with Pharma Commerce, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, addresses the potential impacts of a federal cap on Medicaid provider taxes and how such a policy could affect hospital systems. particularly in states like Michigan that have uniquely […]

President Trump noted that import taxes on pharmaceuticals of up to 200% could come forthcoming. Image Credit: Adobe Stock Images/MohammadXte.com The pharmaceutical industry has been anxiously standing by, waiting on the possibility that tariffs on imports entering the United States could take effect, just not at this potential level. There had been talks over the […]

In a video interview with Pharma Commerce, Marschall Runge, MD, PhD, dean of the University of Michigan Medical School and author of The Great Healthcare Disruption, addresses the potential impacts of a federal cap on Medicaid provider taxes and how such a policy could affect hospital systems. particularly in states like Michigan that have uniquely […]

All of the levies come with a stipulation—if these nations increase their tariffs, the United States will raise them on its end as well. Image Credit: Adobe Stock Images/Zenday.com Yesterday, per AP and CBS News,1,2 US President Donald Trump enacted a multitude of tariffs expected to go into effect on Aug. 1, including a 25% […]

PC: How might this change affect payer negotiations and reimbursement decisions, particularly for innovative or high-cost therapies? Leuchter: When it comes to rare diseases, patients often suffer from a wide range of symptoms—some of which receive more attention from drug developers than others. That’s often because targeting specific symptoms can be a higher-probability path to […]

The trust gap between real-world evidence (RWE)/data and randomized controlled trials is growing. This episode examines when each evidence type is appropriate, how to reduce perceived bias in RWE, and how payer context varies by geography and structure. Insights from academic and payer partnerships show how joint research can establish credibility and unlock market access. […]

A qualitative study explored how representatives from MA plans, kidney care management companies, and dialysis organizations view the expansion and marketing of MA products for individuals with ESKD. Image Credit: Adobe Stock Images/CrystalLight.com By this year, enrollment in Medicare Advantage (MA) plans, which feature private managed care insurers to receive payments from the governments to […]

PC: What risks do you foresee for companies developing first-in-class therapies if patient perspectives are no longer formally incorporated into regulatory discussions? Leuchter: Eliminating patient perspectives from regulatory discussions would remove a key source of value—especially in the context of rare or recently characterized diseases. In many of these cases, there are no formal natural […]

2025 DIA Annual Meeting: Building Patient Centricity into Clinical Trial Software from Day One In an interview with Applied Clinical Trials, Brian Ongioni, chief product officer, uMotif, discussed how the company integrates patient and site feedback from the earliest stages of software development to create intuitive, regulatory-ready digital health tools that reduce burden and improve […]

Image Credit: Adobe Stock Images/TadaImages.com As a result of the Patient Protection and Affordable Care Act (ACA), 24.2 million people enrolled in the health insurance marketplaces this year, a record number.1 However, sustaining that coverage can potentially be a major challenge, given the administrative obstacles that they can face. Why zero-dollar premium plans matter for […]

Preparing for Federal Regulations: Q&A with John Stanford In an interview with Pharmaceutical Executive, John Stanford, executive director at Incubate, emphasized the importance of sustained investment in early-stage biotech to drive long-term innovation and ensure a robust drug development pipeline. Funding Cuts Threaten Diversity in Clinical Research In an interview with Applied Clinical Trials, Kyle […]

Novo Nordisk is growing coverage of its Wegovy injection 2.4 mg in the form of a new deal with WeightWatchers that takes effect July 1. Image Credit: Adobe Stock Images/Syahrir.com Novo Nordisk is growing coverage of its Wegovy (semaglutide) injection 2.4 mg in the form of a new deal with WeightWatchers that takes effect July 1.1 […]

Oncology Care Index Spurs J&J to Address Fragmentation in Cancer Treatment In an interview with Pharmaceutical Executive, Biljana Naumovic, US President, oncology, solid tumor, Johnson & Johnson Innovative Medicine, shared how insights from the company’s Oncology Care Index are shaping efforts to reduce fragmentation in cancer care by expanding community-based clinical research, improving care continuity, […]